IC50 (half-maximum inhibitory concentration) values of sorafenib in high-FGL1 expressing HCC cells (HepG2, Huh7, and Hep3B) were 2–3 times lower than those in low-FGL1 HCC cells (Table 1). The gene discussed is FGL1; the disease is hepatocellular carcinoma.